p-Toluenesulfonic acid monohydrate → Ethyl 2-(5,6-dichloro-1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-3-oxo-butyrate
Reaktionsgleichung
[Cl:1][C:2]1[CH:3]=[C:4]2[C:8](=[CH:9][C:10]=1[Cl:11])[C:7](=[O:12])[N:6]([CH2:13][CH:14]([C:20]1([CH3:25])OCC[O:21]1)[C:15]([O:17][CH2:18][CH3:19])=[O:16])[C:5]2=[O:26].O.C1(C)C=CC(S(O)(=O)=O)=CC=1>>[Cl:11][C:10]1[CH:9]=[C:8]2[C:4](=[CH:3][C:2]=1[Cl:1])[C:5](=[O:26])[N:6]([CH2:13][CH:14]([C:20](=[O:21])[CH3:25])[C:15]([O:17][CH2:18][CH3:19])=[O:16])[C:7]2=[O:12]Komponenten
3
Versuchsvorschrift
Ethyl 2-(5,6-dichloro-1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-3-oxo-butyrate was prepared (171 mg, 34%) in the same manner as described in the above example 6 (20) from ethyl 3-(5,6-dichloro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-2-(2-methyl-[1,3]dioxolan-2-yl)propionate (0.57 g, 1.42 mmol) and p-toluenesulfonic acid monohydrate (50 mg), and the obtained product was identified with the following NMR data.